| 000 | 01864 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516214037.0 | ||
| 264 | 0 | _c20150330 | |
| 008 | 201503s 0 0 eng d | ||
| 022 | _a1879-0844 | ||
| 024 | 7 |
_a10.1002/ejhf.85 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBöhm, Michael | |
| 245 | 0 | 0 |
_aRelationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). _h[electronic resource] |
| 260 |
_bEuropean journal of heart failure _cJul 2014 |
||
| 300 |
_a778-87 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xmortality |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Failure _xdrug therapy |
| 650 | 0 | 4 |
_aHeart Rate _xphysiology |
| 650 | 0 | 4 |
_aHospitalization _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aStroke Volume |
| 650 | 0 | 4 |
_aTetrazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aVentricular Dysfunction, Left _xdrug therapy |
| 700 | 1 | _aPerez, Ana-Cristina | |
| 700 | 1 | _aJhund, Pardeep S | |
| 700 | 1 | _aReil, Jan C | |
| 700 | 1 | _aKomajda, Michel | |
| 700 | 1 | _aZile, Michael R | |
| 700 | 1 | _aMcKelvie, Robert S | |
| 700 | 1 | _aAnand, Inder S | |
| 700 | 1 | _aMassie, Barry M | |
| 700 | 1 | _aCarson, Peter E | |
| 700 | 1 | _aMcMurray, John J V | |
| 773 | 0 |
_tEuropean journal of heart failure _gvol. 16 _gno. 7 _gp. 778-87 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ejhf.85 _zAvailable from publisher's website |
| 999 |
_c23859142 _d23859142 |
||